Surgery Partners Forecasts 4% Q4 Growth, Authorizes $200M Buyback and M&A Spend
In Q4 2025, Surgery Partners forecast growth above 4% despite payer-mix pressure in three surgical-hospital markets from Medicare Advantage access limits and physician turnover. The company approved a $200 million buyback, will allocate $200 million to M&A in 2026 and guides 3% revenue growth evenly split between price and volume.
1. Q4 Growth and Market Pressures
Surgery Partners projected organic growth above 4% in Q4 2025 despite unique headwinds in three surgical-hospital markets. Restricted Medicare Advantage access and unexpected physician transitions drove payer-mix imbalances, with management expecting improvements as new physicians mature on the platform.
2. Share Buyback and M&A Pipeline
The board approved a $200 million share buyback authorization to provide flexibility in capital allocation, alongside plans to deploy at least $200 million toward acquisitions in 2026. Management emphasized a balanced approach between M&A, debt reduction and shareholder returns.
3. 3% Revenue Guidance Split
The company reiterated full-year revenue growth guidance of 3%, noting that the increase is roughly evenly split between price enhancements and volume gains. This balanced split reflects confidence in both market pricing dynamics and procedural volume recovery.
4. Cardiology and ASC Opportunities
The phase-out of the inpatient-only list has opened cardiology procedures—particularly EP and vascular services—to ambulatory surgical centers. Though state restrictions and physician transitions may delay adoption, management sees significant long-term potential in high-value cardiology offerings.